APPENDIX I

ACCOUNTANTS’ REPORT

13.

INTANGIBLE ASSETS, NET

Intangible assets outstanding as of December 31, 2016 and 2017 and March 31, 2018 are

summarized as follows:

As of December 31,

As of March 31,

2016

US$’000

2017

US$’000

2018

US$’000

Finite-lived intangible assets:
Product distribution rights

Gross carrying amount ........................................
Accumulated amortization ...................................

Intangible assets, net...........................................

—
—

—

7,500
(250)

7,250

7,500
(438)

7,062

Product distribution rights consist of distribution rights on the approved cancer therapies
licensed from Celgene, ABRAXANE威, REVLIMID威, and VIDAZA威, and its investigational agent
CC-122 acquired as part of the Celgene transaction. The Group is amortizing the product distribution
rights over a period of 10 years, which is based on the contractual life of such distribution rights.

Amortization expense of intangible assets for the years ended December 31, 2016 and 2017 and
the three months ended March 31, 2017 and 2018 were nil, US$250,000, nil and US$188,000,
respectively. As of March 31, 2018, expected amortization expense for the unamortized finite-lived
intangible assets is approximately US$562,000 for the remainder of 2018, US$750,000 in 2019,
US$750,000 in 2020, US$750,000 in 2021, US$750,000 in 2022, and US$3,500,000 in 2023 and
thereafter.

14.

INCOME TAXES

Cayman Islands

The Company is incorporated in the Cayman Islands. Under the current laws of the Cayman

Islands, the Company is not subject to income tax.

Hong Kong

BeiGene HK is incorporated in Hong Kong. Companies registered in Hong Kong are subject to
Hong Kong profits tax on the taxable income as reported in their respective statutory financial
statements adjusted in accordance with relevant Hong Kong tax laws. The applicable tax rate is 16.5%
in Hong Kong. The Group did not make any provisions for Hong Kong profits tax as there were no
assessable profits derived from or earned in Hong Kong for any of the periods presented. Under the
Hong Kong tax law, BeiGene (Hong Kong) Co., Limited is exempted from income tax on its
foreign-derived income and there are no withholding taxes in Hong Kong on remittance of dividends.

— I-48 —

